✦ LIBER ✦

Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin’s disease

✍ Scribed by Ş. Kömürcü; A. Özet; M. Altundag; F. Arpaci; B. Öztürk; B. Celasun; Y. Tezcan

Publisher: Springer
Year: 2001
Tongue: English
Weight: 43 KB
Volume: 81
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-001-0406-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term remission in a patient with he

Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation

✍ Zaher K. Otrock; Hassan A. Hatoum; Ziad M. Salem; Ayman Tawil; Rami A. Mahfouz; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 164 KB

High-dose chemotherapy and autologous pe

High-dose chemotherapy and autologous peripheral blood stem cell transplantation for treatment of unspecified peripheral T-cell lymphoma presented with hepatosplenomegaly and hypercytokinemia syndrome: report of three cases

✍ J. Tsuchiyama; K. Imajo; T. Yoshino; N. Nanba; A. Toyota; C. Yoshida; K. Fujii; 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 119 KB

Anti-CD20 antibody as consolidation ther

Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation

✍ C. Gemmel; F. Cremer; M. Weis; M. Witzens; G. Moldenhauer; K.-H. Koniczek; U. Im 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 67 KB

The feasibility of neoadjuvant high-dose

The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma : Results of a phase II study

✍ Fikret Arpaci; Selmin Ataergin; Ahmet Ozet; Kaan Erler; Mustafa Basbozkurt; Ayha 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 1 views

## Abstract ## BACKGROUND The primary and secondary objectives of the current study were to improve the ≥ 90% tumor necrosis rate and assess the toxicity profile of the neoadjuvant high‐dose chemotherapy (HDC) regimen, respectively. ## METHODS Twenty‐two patients with AJCC Stage IIB high‐grade o

A randomized trial of chemotherapy with

A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

✍ J.-P. Glossmann; A. Josting; B. Pfistner; U. Paulus; A. Engert; German Hodgkin's 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 90 KB